Patents by Inventor Motoyuki Yajima
Motoyuki Yajima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6232343Abstract: An ophthalmic preparation which exhibits excellent pharmacological effects for various ophthalmic diseases is disclosed. The ophthalmic preparation according to the present invention contains a 4,8-inter-m-phenylene prostaglandin I2 derivative represented by the formula (I): or a pharmaceutically acceptable salt thereof as an effective ingredient.Type: GrantFiled: March 9, 1998Date of Patent: May 15, 2001Assignee: Toray Industries, Inc.Inventors: Takashi Ikari, Yuzuru Matsumura, Tsutomu Nakamura, Motoyuki Yajima, Hajimu Kurumatani, Ayako Kawashima, Masafumi Isogaya, Hisanori Wakita
-
Patent number: 5852050Abstract: The present invention relates to a preparation, particularly a topical preparation, for the therapy of wounds or hemorrhoids, which contains, as an active ingredient, at least one of prostaglandin I.sub.2, prostaglandin E.sub.1 and derivatives of these, particularly beraprost, a derivative of prostaglandin I.sub.2, or a salt thereof, and a method of the therapy of wounds or hemorrhoids, which comprises administering the above active ingredient.Type: GrantFiled: July 9, 1997Date of Patent: December 22, 1998Assignees: Kaken Pharmaceutical Co., Ltd., Toray Industries Inc.Inventors: Makoto Okumura, Toshiaki Okuda, Tsutomu Nakamura, Motoyuki Yajima
-
Patent number: 5679707Abstract: The present invention relates to a preparation, particularly a topical preparation, for the therapy of wounds or hemorrhoids, which contains, as an active ingredient, at least one of prostaglandin I.sub.2, prostaglandin E.sub.1 and derivatives of these, particularly beraprost, a derivative of prostaglandin I.sub.2, or a salt thereof, and a method of the therapy of wounds or hemorrhoids, which comprises administering the above active ingredient.Type: GrantFiled: December 27, 1994Date of Patent: October 21, 1997Assignees: Kaken Pharmaceutical Co., Ltd., Toray Industries Inc.Inventors: Makoto Okumura, Toshiaki Okuda, Tsutomu Nakamura, Motoyuki Yajima
-
Patent number: 5403867Abstract: The present invention relates to a preparation, particularly a topical preparation, for the therapy of wounds or hemorrhoids, which contains, as an active ingredient, at least one of prostaglandin I.sub.2, prostaglandin E.sub.1 and derivatives of these, particularly beraprost, a derivative of prostaglandin I.sub.2, or a salt thereof, and a method of the therapy of wounds or hemorrhoids, which comprises administering the above active ingredient.Type: GrantFiled: November 30, 1993Date of Patent: April 4, 1995Assignees: Kaken Pharmaceutical Co., Ltd., Toray Industries, Inc.Inventors: Makoto Okumura, Toshiaki Okuda, Tsutomu Nakamura, Motoyuki Yajima
-
Patent number: 5049587Abstract: Disclosed are novel opthalmic solutions useful for the treatment of ocular hypertension and glaucoma. These contain mabuterol as a preferred active ingredient.Type: GrantFiled: April 21, 1989Date of Patent: September 17, 1991Assignee: Basotherm GmbHInventors: Taira Okamoto, Motoyuki Yajima
-
Patent number: 5000953Abstract: A novel biologically active substance named Islets-Activating Protein obtained from the cultivation of the miocroorganism Bordetella and having insulin secretion promoting action as well as glucose tolerance improving action for mammals.Type: GrantFiled: March 23, 1989Date of Patent: March 19, 1991Assignee: Kaken Chemical Co., Ltd.Inventors: Michio Ui, Motoyuki Yajima, Chikanori Tomioka, Koichi Hosoda
-
Patent number: 4666931Abstract: A benzofuran derivative having the general formula (I): ##STR1## wherein R.sup.1 is hydrogen atom, a benzyl group, unsubstituted or substituted with a halogen atom or an alkyloxy group, or an alkyl group having 1 to 3 carbon atoms, R.sup.2 is hydrogen atom or an alkyl group having 1 to 3 carbon atoms, R.sup.3 is acetyl group, ethyl group, carboxyl group or 4-methyl-2,5-dioxoimidazolidine-4-yl group, R.sup.4 is hydrogen atom, hydroxyl group, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 9 carbon atoms, carboxymethoxy group, nitro group, acetoamino group, a benzylozy group unsubstituted or substituted with a halogen atom, nitro group or an alkyloxy group or a group having the formula: --OR.sup.6, wherein R.sup.6 is an alkenyl group having 2 to 4 carbon atoms or an alkyl group having 2 to 3 carbon atoms having a halogen atom, cyano group or oxo group, R.sup.5 is hydrogen atom or methylenedioxy group together with R.sup.Type: GrantFiled: December 27, 1985Date of Patent: May 19, 1987Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Yoshitaka Ohishi, Michiko Nagahara, Norio Kajikawa, Motoyuki Yajima, Katsumi Nogimori, Shigeki Kurokawa
-
Patent number: 4609736Abstract: A rhodanine derivative having the following general formula (I): ##STR1## wherein R is an acyclic alkyl group having 2 to 10 carbon atoms which may be substituted by a halogen atom or an acyclic alkenyl group having 2 to 19 carbon atoms which may be substituted by a halogen atom; or a nontoxic salt thereof. The rhodanine derivative has potent platelet aggregation inhibiting activity and aldose reductase inhibiting activity and therefore is useful as a therapeutic agent for diabetic complications.Type: GrantFiled: November 28, 1984Date of Patent: September 2, 1986Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Yoshitaka Ohishi, Michiko Nagahara, Yoshitaka Takehisa, Motoyuki Yajima, Shigeki Kurokawa, Norio Kajikawa, Akira Itoh
-
Patent number: 4609549Abstract: The present invention relates to biologically active substances obtained by reacting Islets-Activating Protein having an insulin secretion promoting action with a carbonyl compound in the presence of a reducing agent; to anti-diabetic composition in dosage unit form comprising the substance of the present invention; to pertussis vaccine in dosage unit form comprising the substance of the present invention; and to a process for the preparation of the same. The substances of the present invention are suppressed in leukocytosis-promoting effect.Type: GrantFiled: May 3, 1984Date of Patent: September 2, 1986Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Katsumi Nogimori, Makoto Tamura, Shigeki Kurokawa, Motoyuki Yajima
-
Patent number: 4606860Abstract: A rhodanine derivative having the following general formula (I): ##STR1## wherein R is a mono- or di-alkylamino group having 1 to 6 carbon atoms which may be substituted by a hydroxyl group; an alkenylamino group having 3 to 6 carbon atoms; a phenylamino group, the benzene ring of which may be substituted by a lower alkyl group, a lower alkoxyl group, phenyl group or a halogen atom; or a cyclic amino group which may contain in the ring an oxygen atom or a nitrogen atom to which a lower alkyl group is attached; or a nontoxic salt thereof. The rhodanine derivative has potent platelet aggregation inhibiting activity and aldose reductase inhibiting activity and therefore is useful as a therapeutic agent for diabetic complications.Type: GrantFiled: November 28, 1984Date of Patent: August 19, 1986Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Michiko Nagahara, Yoshitaka Ohishi, Motoyuki Yajima, Katsumi Nogimori, Shigeki Kurokawa, Norio Kajikawa
-
Patent number: 4234570Abstract: Novel biologically active substances prepared by dissociating the protein obtained from the cultivation of the microorganism Bordetella and having insulin secretion promoting action as well as glucose tolerance improving action for mammals.Type: GrantFiled: June 1, 1978Date of Patent: November 18, 1980Assignee: Kakenyaku Kako Kabushiki KaishaInventors: Yoshinori Kanbayashi, Michio Ui, Koichi Hosoda, Akira Ito, Shigeki Kurokawa, Akio Terashima, Isamu Takahashi, Motoyuki Yajima, Chikanori Tomioka, Tsutomu Nakamura, Katsumi Nogimori, Taira Okamoto